This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, X.-F. Articles by Ritz, J. Search for Related Content PubMed PubMed Citation Articles by Yang, X.-F. Articles by Ritz, J.

CML28 Is a Broadly Immunogenic Antigen, Which Is Overexpressed in Tumor Cells¹

Center for Hematologic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115

Donor lymphocyte infusion (DLI) reliably induces durable remission in 75–80% of patients with relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation. To identify immunological targets of the graft-versus-leukemia response (GVL) after DLI, we used CML post-DLI responder sera to screen a CML cDNA expression library. One of the antigens identified in this screen is a M_r 28,000 protein, termed CML28. CML28 is identical to hRrp46p, a component of the human exosome, a multiprotein complex involved in the 3' processing of RNA. Components of the human exosome include known autoantigens, such as PMScl-100, an autoantibody target in patients with polymyositis, scleroderma, or polymyositis-scleroderma overlap syndrome. Recombinant CML28-GST fusion protein was purified, and used in Western blot and ELISA to demonstrate the development of a high-titer CML28-specific IgG antibody response in a patient with relapsed CML who responded to DLI. Northern blotting demonstrated that CML28 is highly expressed in a variety of hematopoietic and epithelial tumor cell lines, but not in normal hematopoietic tissues or other normal tissue, with the exception of testis. Purified recombinant CML28 was used to generate a CML28-specific murine monoclonal antibody. Western blotting with CML28 monoclonal antibody against whole-cell lysates derived from blood and marrow of normal donors and patients with leukemia revealed high expression of this antigen in tumor but not in normal samples. Because CML28 was highly expressed in epithelial tumor cell lines, anti-CML28 responses were also examined in patients with solid tumors. By ELISA, we found specific serological responses in 10–33% of patients with lung cancer, melanoma, and prostate cancer. Our studies suggest that immunogenicity of CML28 is likely because of overexpression of this antigen in tumor cells. Moreover, given its expression and immunogenicity in a wide variety of malignancies, CML28 merits additional evaluation as a target for antigen-specific immunotherapy.

This article has been cited by other articles:

				S. Baskar, J. M. Suschak, I. Samija, R. Srinivasan, R. W. Childs, S. Z. Pavletic, M. R. Bishop, and C. Rader A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display Blood, November 12, 2009; 114(20): 4494 - 4502. [Abstract] [Full Text] [PDF]

				S. Kammler, S. Lykke-Andersen, and T. H. Jensen The RNA Exosome Component hRrp6 Is a Target for 5-Fluorouracil in Human Cells Mol. Cancer Res., June 1, 2008; 6(6): 990 - 995. [Abstract] [Full Text] [PDF]

				Z. Xiong, E. Liu, Y. Yan, R. T. Silver, F. Yang, I. H. Chen, Y. Chen, S. Verstovsek, H. Wang, J. Prchal, et al. An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions J. Immunol., October 1, 2006; 177(7): 4907 - 4916. [Abstract] [Full Text] [PDF]

				G.-C. Chang, K.-J. Liu, C.-L. Hsieh, T.-S. Hu, S. Charoenfuprasert, H.-K. Liu, K.-T. Luh, L.-H. Hsu, C.-W. Wu, C.-C. Ting, et al. Identification of {alpha}-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes. Clin. Cancer Res., October 1, 2006; 12(19): 5746 - 5754. [Abstract] [Full Text] [PDF]

				S Abdul-Rasool, S H Kidson, E Panieri, D Dent, K Pillay, and G S Hanekom An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. J. Clin. Pathol., March 1, 2006; 59(3): 289 - 297. [Abstract] [Full Text] [PDF]

				C. J. Wu, M. Biernacki, J. L. Kutok, S. Rogers, L. Chen, X.-F. Yang, R. J. Soiffer, and J. Ritz Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells Clin. Cancer Res., June 15, 2005; 11(12): 4504 - 4511. [Abstract] [Full Text] [PDF]

				H. Hieronymus, M. C. Yu, and P. A. Silver Genome-wide mRNA surveillance is coupled to mRNA export Genes & Dev., November 1, 2004; 18(21): 2652 - 2662. [Abstract] [Full Text] [PDF]

				M. Monji, T. Nakatsura, S. Senju, Y. Yoshitake, M. Sawatsubashi, M. Shinohara, T. Kageshita, T. Ono, A. Inokuchi, and Y. Nishimura Identification of a Novel Human Cancer/Testis Antigen, KM-HN-1, Recognized by Cellular and Humoral Immune Responses Clin. Cancer Res., September 15, 2004; 10(18): 6047 - 6057. [Abstract] [Full Text] [PDF]

				Y. Yan, L. Phan, F. Yang, M. Talpaz, Y. Yang, Z. Xiong, B. Ng, N. A. Timchenko, C. J. Wu, J. Ritz, et al. A Novel Mechanism of Alternative Promoter and Splicing Regulates the Epitope Generation of Tumor Antigen CML66-L J. Immunol., January 1, 2004; 172(1): 651 - 660. [Abstract] [Full Text] [PDF]

				R. Raijmakers, W. V. Egberts, W. J. van Venrooij, and G. J. M. Pruijn The Association of the Human PM/Scl-75 Autoantigen with the Exosome Is Dependent on a Newly Identified N Terminus J. Biol. Chem., August 15, 2003; 278(33): 30698 - 30704. [Abstract] [Full Text] [PDF]